Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53

作者: H. Yoon , S. Liyanarachchi , F. A. Wright , R. Davuluri , J. C. Lockman

DOI: 10.1073/PNAS.242597299

关键词: Gene expression profilingGeneticsCandidate geneGene dosageTranscriptional regulationGene targetingGeneIntronGene expressionBiology

摘要: TP53 does not fully comply with the Knudson model [Knudson, A. G., Jr. (1971) Proc. Natl. Acad. Sci. USA 68, 820–823] in that a reduction of constitutional expression p53 may be sufficient for tumor predisposition . This finding suggests gene-dosage effect function. To determine whether gene dosage affects transcriptional regulation target genes, we performed oligonucleotide-array analysis by using human cells wild-type (p53 +/+), or one +/−), both −/−) alleles disrupted homologous recombination. We identified 35 genes whose is significantly correlated to TP53. These are involved variety cellular processes including signal transduction, cell adhesion, and transcription regulation. Several them neurogenesis neural crest migration, developmental which known play role. Motif search revealed highly expressed +/+ +/− cells, several contain putative consensus binding site (bs), suggesting they could directly regulated p53. Among those chose CSPG2 (which encodes versican) further study because it contains bona fide bs its first intron correlates dosage. By vitro vivo assays, showed transactivated In conclusion, developed strategy demonstrate many affected their expression. report candidate as potential downstream targets nonstressed cells. them, validated being Our method provides useful tool elucidate additional mechanisms exerts functions.

参考文章(41)
Peter Beighton, Greta Beighton, de la Chapelle, A. The Person Behind the Syndrome. pp. 209- 209 ,(1997) , 10.1007/978-1-4471-0925-9_118
K. W. Kohn, D. J. Rivet, A. J. Fornace, Qimin Zhan, M. L. Smith, Saijun Fan, P. M. O'connor, D. Duba, Disruption of p53 Function Sensitizes Breast Cancer MCF-7 Cells to Cisplatin and Pentoxifylline Cancer Research. ,vol. 55, pp. 1649- 1654 ,(1995)
Joseph R. Nevins, James DeGregori, Laszlo Jakoi, Gustavo Leone, Functional analysis of E2F transcription factor Methods in Enzymology. ,vol. 283, pp. 205- 219 ,(1997) , 10.1016/S0076-6879(97)83017-0
A Zauberman, M Oren, Y Barak, D L George, T Juven, Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene Oncogene. ,vol. 8, pp. 3411- 3416 ,(1993)
M F Naso, D R Zimmermann, R V Iozzo, Characterization of the complete genomic structure of the human versican gene and functional analysis of its promoter. Journal of Biological Chemistry. ,vol. 269, pp. 32999- 33008 ,(1994) , 10.1016/S0021-9258(20)30090-9
Hiroshi Tanaka, Hirofumi Arakawa, Tatsuya Yamaguchi, Kenji Shiraishi, Seisuke Fukuda, Kuniko Matsui, Yoshiki Takei, Yusuke Nakamura, A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage Nature. ,vol. 404, pp. 42- 49 ,(2000) , 10.1038/35003506
Wayne Tilley, Kieran McCaul, David Horsfall, Carmela Ricciardelli, Keiko Mayne, Pam Sykes, Villis Marshall, Wendy Raymond, John Skinner, Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clinical Cancer Research. ,vol. 3, pp. 983- 992 ,(1997)
Sundaresan Venkatachalam, Yu‐Ping Shi, Stephen N Jones, Hannes Vogel, Allan Bradley, Dan Pinkel, Lawrence A Donehower, Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation The EMBO Journal. ,vol. 17, pp. 4657- 4667 ,(1998) , 10.1093/EMBOJ/17.16.4657
J. D. Dignam, R. M. Lebovitz, R. G. Roeder, Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei Nucleic Acids Research. ,vol. 11, pp. 1475- 1489 ,(1983) , 10.1093/NAR/11.5.1475